Navigation Links
Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
Date:9/30/2010

ible," said Steve Harris, Circassia's CEO. "Since the founding of Circassia just four years ago, our ToleroMune(R) technology has successfully completed multiple phase II studies, and we now have four therapies in mid-stage development, targeting some of the most common allergies in the world. As a result, our growing clinical database demonstrates the potential of our novel T-cell vaccines to provide allergy sufferers with short, simple and convenient treatment, whilst minimising the risk of severe and sometimes life-threatening side effects associated with many existing immunotherapies."

About Circassia's allergy T-cell vaccines

Circassia's range of allergy T-cell vaccines is based on its proprietary ToleroMune(R) technology. This technology utilises allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia's allergy T-cell vaccines show that short treatment regimes can greatly reduce patients' allergic reactions, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy treatments offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceu
'/>"/>

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine
2. Circassia Acquires North American and Japanese Rights to Dopexamine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... 2011 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the ... issue of the journal Science regarding the ... omecamtiv mecarbil, and the potential therapeutic role that this ... failure. This publication reveals, for the first time ...
... and ST. GALLEN, Switzerland, March 17, 2011 Genomic ... results from nine studies utilizing the Onco type ... 12th Annual St. Gallen International Breast Cancer Conference in ... data that demonstrated the knowledge of a patient,s Recurrence ...
... Inc., a consulting firm that specializes in maximizing sales ... as Executive Account Director. Weimer has gained recognition and ... develop and inspire his teams to attain personal excellence ... organization,s goals. Delta Point CEO and founder ...
Cached Biology Technology:Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science 2Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science 3Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 2Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 3Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 4Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 5Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 6Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 7Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 8Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2
(Date:7/9/2014)... piece of the puzzle behind nature,s ability to ... help advance the development of artificial photosynthesis for ... by an international collaboration of scientists led by ... Lab) and the SLAC National Accelerator Laboratory. ... (LCLS), the world,s most powerful x-ray laser, the ...
(Date:7/9/2014)... of increasing concern about the prevalence of antibiotic-resistant ... promising new pathway to disabling disease: blocking bacteria,s ... scientists showed how bacterial siderophore, a small molecule, ... fan bacterial growth as well as how ... infection process. Their findings appear in a recent ...
(Date:7/9/2014)... penguins shows that the population is 3.79 million ... estimated. Adlie penguins have long been considered a ... effects of climate change and fishing in the ... researchers from Stony Brook University and University of ... regular monitoring of Adlie penguins across their entire ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... researchers from Princeton University and the Drexel University College ... malaria breaks down an important amino acid in its ... By depleting this substance called arginine, the parasite may ... disease. The scientists believe that shedding light on ...
... and University of Malaya (UM) today announced the establishment ... This is the first Centre of its kind in ... communities in terms of their diet and disease, conducting ... environment and health, providing assistance for the national cancer ...
... of the oil in the ocean bubbles up naturally from ... was of no value. Likewise, NASA satellites collect thousands of ... of it gets passed over because no one thinks there ... black gold bubbling up from an otherwise undistinguished mass of ...
Cached Biology News:Malaria parasite zeroes in on molecule to enhance its survival, team finds 2Malaria parasite zeroes in on molecule to enhance its survival, team finds 3Queen's University Belfast improves Malaysian public health 2Scientists find black gold amidst overlooked data 2Scientists find black gold amidst overlooked data 3
... (M-MLV RT) is an RNA-dependent DNA polymerase that ... messenger RNA templates (>5kb). The enzyme is a ... consists of a single subunit with a molecular ... M-MLV RT is weaker than the commonly used ...
... the determination of digitonin and digoxin. Physical form: ... 4 and 0.06% NaCl Preparation Note: Sodium ... Biophys. Res. Commun., 19, 755 (1965). Unit ... inorganic phosphorus from ATP per min at pH ...
kismet (dK-20)...
... design allows "4 gels in one tank",electrophoresis. ... to run 200,samples or more in one ... four,horizontal gels. To ensure even migration, the ... of gels being run. Ideal for,high throughput ...
Biology Products: